Pathogenesis and virulence of coronavirus disease: Comparative pathology of animal models for COVID-19

References

• Bukhari K, Mulley G, Gulyaeva AA, et al. Description and initial characterization of metatranscriptomic nidovirus-like genomes from the proposed new family abyssoviridae, and from a sister group to the coronavirinae, the proposed genus alphaletovirus. Virology. 2018;524:160–22. doi: 10.1016/j.virol.2018.08.010
   PubMed Web of Science ®Google Scholar
• Knipe DM, Howley P. Fields virology. United States: Wolters Kluwer Health; 2013.
   Google Scholar
• Booth TF, Kournikakis B, Bastien N, et al. Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis. 2005;191(9):1472–1477. doi: 10.1086/429634
   PubMed Web of Science ®Google Scholar
• Kim S-H, Chang SY, Sung M, et al. Extensive viable middle east respiratory syndrome (MERS) coronavirus contamination in air and surrounding environment in MERS Isolation wards. Clin Infect Dis. 2016;63(3):363–369. doi: 10.1093/cid/ciw239
   PubMed Web of Science ®Google Scholar
• Santarpia JL, Rivera DN, Herrera VL, et al. Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care. Sci Rep. 2020;10(1):12732. doi: 10.1038/s41598-020-69286-3
   PubMed Web of Science ®Google Scholar
• Zhou J, Li C, Zhao G, et al. Human intestinal tract serves as an alternative infection route for middle east respiratory syndrome coronavirus. Sci Adv. 2017;3(11):eaao4966. doi: 10.1126/sciadv.aao4966
   PubMed Web of Science ®Google Scholar
• Jiao L, Li H, Xu J, et al. The gastrointestinal tract is an alternative route for sars-cov-2 infection in a nonhuman primate model. Gastroenterology. 2021;160(5):1647–1661. doi: 10.1053/j.gastro.2020.12.001
   PubMed Web of Science ®Google Scholar
• Vlasova AN, Kenney SP, Jung K, et al. Deltacoronavirus evolution and transmission: Current scenario and evolutionary perspectives. Front Vet Sci. 2021;7. doi: 10.3389/fvets.2020.626785
   PubMed Web of Science ®Google Scholar
• Malone B, Urakova N, Snijder EJ, et al. Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design. Nat Rev Mol Cell Biol. 2022;23(1):21–39. doi: 10.1038/s41580-021-00432-z
   PubMed Web of Science ®Google Scholar
• Payne S. Family coronaviridae. Viruses. 2017;149–158. doi: 10.1016/B978-0-12-803109-4.00017-9
   PubMedGoogle Scholar
• Liu X, Zhang X, Lu Z, et al. Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection. Biomed Pharmacother. 2021;133:111035. doi:10.1016/j.biopha.2020.111035
   PubMed Web of Science ®Google Scholar
• Redondo N, Zaldívar-López S, Garrido JJ, et al. SARS-CoV-2 accessory proteins in viral pathogenesis: knowns and unknowns. Front Immunol. 2021;12. doi: 10.3389/fimmu.2021.708264
   PubMed Web of Science ®Google Scholar
• Sparrer MN, Hodges NF, Sherman T, et al. Role of spillover and spillback in SARS-CoV-2 transmission and the importance of one health in understanding the dynamics of the COVID-19 pandemic. J Clin Microbiol. 2023;61(7):e0161022. doi: 10.1128/jcm.01610-22
   PubMed Web of Science ®Google Scholar
• Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–192. doi: 10.1038/s41579-018-0118-9
   PubMed Web of Science ®Google Scholar
• Corman VM, Baldwin HJ, Tateno AF, et al. Evidence for an ancestral association of human coronavirus 229E with bats. J Virol. 2015;89(23):11858–11870. doi: 10.1128/JVI.01755-15
   PubMed Web of Science ®Google Scholar
• Tao Y, Shi M, Chommanard C, et al. Surveillance of bat coronaviruses in Kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history. J Virol. 2017;91(5):e01953–16. doi: 10.1128/JVI.01953-16
   PubMed Web of Science ®Google Scholar
• Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003;302(5643):276–278. doi: 10.1126/science.1087139
   PubMed Web of Science ®Google Scholar
• Tu C, Crameri G, Kong X, et al. Antibodies to SARS coronavirus in civets. Emerg Infect Dis. 2004;10(12):2244–2248. doi: 10.3201/eid1012.040520
   PubMed Web of Science ®Google Scholar
• Corman VM, Eckerle I, Memish ZA, et al. Link of a ubiquitous human coronavirus to dromedary camels. Proc Natl Acad Sci U S A. 2016;113(35):9864–9869. doi: 10.1073/pnas.1604472113
   PubMed Web of Science ®Google Scholar
• Lam TT-Y, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature. 2020;583(7815):282–285. doi: 10.1038/s41586-020-2169-0
   PubMed Web of Science ®Google Scholar
• Ellwanger JH, Chies JAB. Zoonotic spillover: understanding basic aspects for better prevention. Genet Mol Biol. 2021;44(1 suppl 1):e20200355. doi: 10.1590/1678-4685-gmb-2020-0355
   PubMed Web of Science ®Google Scholar
• Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020;584(7820):257–261. doi: 10.1038/s41586-020-2405-7
   PubMed Web of Science ®Google Scholar
• Watson OJ, Barnsley G, Toor J, et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293–1302. doi: 10.1016/S1473-3099(22)00320-6
   PubMed Web of Science ®Google Scholar
• He Y, Lu H, Siddiqui P, et al. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol. 2005;174(8):4908–4915. doi: 10.4049/jimmunol.174.8.4908
   PubMed Web of Science ®Google Scholar
• Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584(7819):115–119. doi: 10.1038/s41586-020-2380-z
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211. doi: 10.1038/s41591-021-01377-8
   PubMed Web of Science ®Google Scholar
• Toussi SS, Hammond JL, Gerstenberger BS, et al. Therapeutics for COVID-19. Nat Microbiol. 2023;8(5):771–786. doi: 10.1038/s41564-023-01356-4
   PubMed Web of Science ®Google Scholar
• Ng DL, Al Hosani F, Keating MK, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of middle east respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol. 2016;186(3):652–658. doi: 10.1016/j.ajpath.2015.10.024
   PubMed Web of Science ®Google Scholar
• Alsaad KO, Hajeer AH, Al Balwi M, et al. Histopathology of Middle East respiratory syndrome coronovirus (MERS -CoV) infection – clinicopathological and ultrastructural study. Histopathology. 2018;72(3):516–524. doi: 10.1111/his.13379
   PubMed Web of Science ®Google Scholar
• Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289(21):2801–2809. doi: 10.1001/jama.289.21.JOC30885
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi: 10.1038/s41586-020-2012-7
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. doi: 10.1001/jama.2020.1585
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Pan L, Mu M, Yang P, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020;115(5):766–773. doi: 10.14309/ajg.0000000000000620
   PubMed Web of Science ®Google Scholar
• Borsetto D, Hopkins C, Philips V, et al. Self-reported alteration of sense of smell or taste in patients with COVID-19: a systematic review and meta-analysis on 3563 patients. Rhinology. 2020;58:430–436. doi: 10.4193/Rhin20.185
   PubMed Web of Science ®Google Scholar
• Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–146. doi: 10.1038/s41579-022-00846-2
   PubMed Web of Science ®Google Scholar
• Millet JK, Jaimes JA, Whittaker GR. Molecular diversity of coronavirus host cell entry receptors. FEMS Microbiol Rev. 2021;45(3):fuaa057. doi: 10.1093/femsre/fuaa057
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454. doi: 10.1038/nature02145
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi: 10.1016/j.cell.2020.02.052
   PubMed Web of Science ®Google Scholar
• Acute respiratory distress syndrome: the berlin definition. JAMA. 2012;307 23. doi: 10.1001/jama.2012.5669
   Web of Science ®Google Scholar
• Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of middle east respiratory syndrome coronavirus. N Engl J Med. 2013;369(5):407–416. doi: 10.1056/NEJMoa1306742
   PubMed Web of Science ®Google Scholar
• Clausen TM, Sandoval DR, Spliid CB, et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell. 2020;183(4):1043–1057.e15. doi: 10.1016/j.cell.2020.09.033
   PubMed Web of Science ®Google Scholar
• Hofmann H, Pyrc K, van der Hoek L, et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A. 2005;102(22):7988–7993. doi: 10.1073/pnas.0409465102
   PubMed Web of Science ®Google Scholar
• Turner AJ. ACE2 cell biology, regulation, and physiological functions. The Protective Arm Of The Renin Angiotensin System (RAS). 2015;185–189. doi: 10.1016/B978-0-12-801364-9.00025-0
   Google Scholar
• Hamming I, Timens W, Bulthuis M, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637. doi: 10.1002/path.1570
   PubMed Web of Science ®Google Scholar
• Li M-Y, Li L, Zhang Y, et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Diseases Poverty. 2020;9(1):45. doi: 10.1186/s40249-020-00662-x
   PubMed Web of Science ®Google Scholar
• Qi J, Zhou Y, Hua J, et al. The scRNA-seq expression profiling of the receptor ACE2 and the Cellular Protease TMPRSS2 Reveals human organs susceptible to SARS-CoV-2 infection. Int J Environ Res Public Health. 2021;18(1):284. doi: 10.3390/ijerph18010284
   PubMed Web of Science ®Google Scholar
• Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254. doi: 10.1038/nature12005
   PubMed Web of Science ®Google Scholar
• Meyerholz DK, Lambertz AM, McCray PB. Dipeptidyl peptidase 4 distribution in the human respiratory tract: implications for the middle east respiratory syndrome. Am J Pathol. 2016;186(1):78–86. doi: 10.1016/j.ajpath.2015.09.014
   PubMed Web of Science ®Google Scholar
• Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60(7):1917–1925. doi: 10.2337/db10-1707
   PubMed Web of Science ®Google Scholar
• Fukasawa KM, Fukasawa K, Sahara N, et al. Immunohistochemical localization of dipeptidyl aminopeptidase IV in rat kidney, liver, and salivary glands. J Histochem Cytochem. 1981;29(3):337–343. doi: 10.1177/29.3.6787113
   PubMed Web of Science ®Google Scholar
• Yeager CL, Ashmun RA, Williams RK, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature. 1992;357(6377):420–422. doi: 10.1038/357420a0
   PubMed Web of Science ®Google Scholar
• Li BX, Ge JW, Li YJ. Porcine aminopeptidase N is a functional receptor for the PEDV coronavirus. Virology. 2007;365(1):166–172. doi: 10.1016/j.virol.2007.03.031
   PubMed Web of Science ®Google Scholar
• Tresnan DB, Levis R, Holmes KV. Feline aminopeptidase N serves as a receptor for feline, canine, porcine, and human coronaviruses in serogroup I. J Virol. 1996;70(12):8669–8674. doi: 10.1128/jvi.70.12.8669-8674.1996
   PubMed Web of Science ®Google Scholar
• Krempl C, Schultze B, Herrler G. Analysis of cellular receptors for human coronavirus OC43. Adv Exp Med Biol. 1995;380:371–374.
   PubMedGoogle Scholar
• Ahn JH, Kim J, Hong SP, et al. Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19. J Clin Invest. 2021;1485171(13):148517. doi: 10.1172/JCI148517
   Google Scholar
• Khan M, Yoo S-J, Clijsters M, et al. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. Cell. 2021;184(24):5932–5949.e15. doi: 10.1016/j.cell.2021.10.027
   PubMed Web of Science ®Google Scholar
• Hou YJ, Okuda K, Edwards CE, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 2020;182(2):429–446.e14. doi: 10.1016/j.cell.2020.05.042
   PubMed Web of Science ®Google Scholar
• Wolff G, Limpens RWAL, Zevenhoven-Dobbe JC, et al. A molecular pore spans the double membrane of the coronavirus replication organelle. Science. 2020;369(6509):1395–1398. doi: 10.1126/science.abd3629
   PubMed Web of Science ®Google Scholar
• Knoops K, Kikkert M, Worm SHEVD, et al. SARS-Coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 2008;6(9):e226. doi: 10.1371/journal.pbio.0060226
   PubMed Web of Science ®Google Scholar
• Menachery VD, Debbink K, Baric RS. Coronavirus non-structural protein 16: evasion, attenuation, and possible treatments. Virus Res. 2014;194:191–199. doi:10.1016/j.virusres.2014.09.009
   PubMed Web of Science ®Google Scholar
• Siu K-L, Kok K-H, Ng M-HJ, et al. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3·TANK·TBK1/IKKϵ complex. J Biol Chem. 2009;284(24):16202–16209. doi: 10.1074/jbc.M109.008227
   PubMed Web of Science ®Google Scholar
• Thoms M, Buschauer R, Ameismeier M, et al. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science. 2020;369(6508):1249–1255. doi: 10.1126/science.abc8665
   PubMed Web of Science ®Google Scholar
• Banerjee AK, Blanco MR, Bruce EA, et al. SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses. Cell. 2020;183(5):1325–1339.e21. doi: 10.1016/j.cell.2020.10.004
   PubMed Web of Science ®Google Scholar
• Thornbrough JM, Jha BK, Yount B, et al. Middle east respiratory syndrome coronavirus NS4b protein inhibits host RNase L activation. MBio. 2016;7(2):e00258. doi: 10.1128/mBio.00258-16
   PubMed Web of Science ®Google Scholar
• Diamond MS, Kanneganti T-D. Innate immunity: the first line of defense against SARS-CoV-2. Nat Immunol. 2022;23(2):165–176. doi: 10.1038/s41590-021-01091-0
   PubMed Web of Science ®Google Scholar
• Sievers BL, Cheng MTK, Csiba K, et al. SARS-CoV-2 and innate immunity: the good, the bad, and the “goldilocks”. Cell Mol Immunol. 2023;21(2):171–183. doi: 10.1038/s41423-023-01104-y
   PubMedGoogle Scholar
• Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570. doi: 10.1126/science.abd4570
   PubMed Web of Science ®Google Scholar
• Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. doi: 10.1126/science.abd4585
   PubMed Web of Science ®Google Scholar
• Blanco-Melo D, Nilsson-Payant BE, Liu W-C, et al. Imbalanced Host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–1045.e9. doi: 10.1016/j.cell.2020.04.026
   PubMed Web of Science ®Google Scholar
• Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718–724. doi: 10.1126/science.abc6027
   PubMed Web of Science ®Google Scholar
• Zhu L, Yang P, Zhao Y, et al. Single-cell sequencing of peripheral mononuclear cells reveals distinct immune response landscapes of COVID-19 and influenza patients. Immunity. 2020;53(3):685–696.e3. doi: 10.1016/j.immuni.2020.07.009
   PubMed Web of Science ®Google Scholar
• Zhou Z, Ren L, Zhang L, et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020;27(6):883–890.e2. doi: 10.1016/j.chom.2020.04.017
   PubMed Web of Science ®Google Scholar
• Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci Immunol. 2020;5(49):eabd1554. doi: 10.1126/sciimmunol.abd1554
   PubMed Web of Science ®Google Scholar
• Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: a randomized clinical trial. Int Immunopharmacol. 2020;88:106903. doi: 10.1016/j.intimp.2020.106903
   PubMed Web of Science ®Google Scholar
• Repurposed Antiviral Drugs for COVID-19 — Interim WHO Solidarity Trial Results. N Engl J Med NEJMoa, 2023184 (2020) doi:10.1056/NEJMoa2023184.
   Google Scholar
• Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(2):196–206. doi: 10.1016/S2213-2600(20)30511-7
   PubMed Web of Science ®Google Scholar
• Jhuti D, Rawat A, Guo CM, et al. Interferon treatments for SARS-CoV-2: challenges and opportunities. Infect Dis Ther. 2022;11(3):953–972. doi: 10.1007/s40121-022-00633-9
   PubMed Web of Science ®Google Scholar
• Reis G, Moreira Silva EAS, Medeiros Silva DC, et al. Early treatment with pegylated interferon lambda for covid-19. N Engl J Med. 2023;388(6):518–528. doi: 10.1056/NEJMoa2209760
   PubMed Web of Science ®Google Scholar
• Interferons. COVID-19 Treatment Guidelines https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/interferons/.
   Google Scholar
• Bryce C, Grimes Z, Pujadas E, et al. Pathophysiology of SARS-CoV-2: the mount sinai COVID-19 autopsy experience. Mod Pathol. 2021;34(8):1456–1467. doi: 10.1038/s41379-021-00793-y
   PubMed Web of Science ®Google Scholar
• Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20(10):1135–1140. doi: 10.1016/S1473-3099(20)30434-5
   PubMed Web of Science ®Google Scholar
• Polak SB, Van Gool IC, Cohen D, et al. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol. 2020;33(11):2128–2138. doi: 10.1038/s41379-020-0603-3
   PubMed Web of Science ®Google Scholar
• Tse GM-K, To KF, Chan PK, et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol. 2004;57(3):260–265. doi: 10.1136/jcp.2003.013276
   PubMed Web of Science ®Google Scholar
• Hwang DM, Chamberlain DW, Poutanen SM, et al. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol. 2005;18(1):1–10. doi: 10.1038/modpathol.3800247
   PubMed Web of Science ®Google Scholar
• Franks TJ, Chong PY, Chui P, et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum Pathol. 2003;34(8):743–748. doi: 10.1016/S0046-8177(03)00367-8
   PubMed Web of Science ®Google Scholar
• Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007;170(4):1136–1147. doi: 10.2353/ajpath.2007.061088
   PubMed Web of Science ®Google Scholar
• Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. N Engl J Med. 2020;383(2):120–128. doi: 10.1056/NEJMoa2015432
   PubMed Web of Science ®Google Scholar
• Miggiolaro AFRS, da Silva FPG, Wiedmer DB, et al. COVID-19 and pulmonary angiogenesis: the possible role of hypoxia and hyperinflammation in the overexpression of proteins involved in alveolar vascular dysfunction. Viruses. 2023;15(3):706. doi: 10.3390/v15030706
   PubMed Web of Science ®Google Scholar
• Konopka KE, Nguyen T, Jentzen JM, et al. Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 infection is morphologically indistinguishable from other causes of DAD. Histopathology. 2020;77(4):570–578. doi: 10.1111/his.14180
   PubMed Web of Science ®Google Scholar
• Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19(11):919–929. doi: 10.1016/S1474-4422(20)30308-2
   PubMed Web of Science ®Google Scholar
• Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831–1833.e3. doi: 10.1053/j.gastro.2020.02.055
   PubMed Web of Science ®Google Scholar
• Diao B, Wang C, Wang R, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2021;12(1):2506. doi: 10.1038/s41467-021-22781-1
   PubMed Web of Science ®Google Scholar
• Kissling S, Rotman S, Gerber C, et al. Collapsing glomerulopathy in a COVID-19 patient. Kidney Int. 2020;98(1):228–231. doi: 10.1016/j.kint.2020.04.006
   PubMed Web of Science ®Google Scholar
• Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13. doi: 10.1016/j.trsl.2020.04.007
   PubMed Web of Science ®Google Scholar
• Scobey T, Yount BL, Sims AC, et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proceedings of the National Academy of Sciences. 2013;110:16157–16162.
   PubMed Web of Science ®Google Scholar
• Bao L, Deng W, Huang B, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020;583(7818):830–833. doi: 10.1038/s41586-020-2312-y
   PubMed Web of Science ®Google Scholar
• Sun J, Zhuang Z, Zheng J, et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell. 2020;182(3):734–743.e5. doi: 10.1016/j.cell.2020.06.010
   PubMed Web of Science ®Google Scholar
• Glass WG, Subbarao K, Murphy B, et al. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol. 2004;173(6):4030–4039. doi: 10.4049/jimmunol.173.6.4030
   PubMed Web of Science ®Google Scholar
• McCray PB, Pewe L, Wohlford-Lenane C, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81(2):813–821. doi: 10.1128/JVI.02012-06
   PubMed Web of Science ®Google Scholar
• Yinda CK, Port JR, Bushmaker T, et al. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. PLOS Pathog. 2021;17(1):e1009195. doi: 10.1371/journal.ppat.1009195
   PubMed Web of Science ®Google Scholar
• Oladunni FS, Park J-G, Pino PA, et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun. 2020;11(1):6122. doi: 10.1038/s41467-020-19891-7
   PubMed Web of Science ®Google Scholar
• Sun S-H, Chen Q, Gu H-J, et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe. 2020;28(1):124–133.e4. doi: 10.1016/j.chom.2020.05.020
   PubMed Web of Science ®Google Scholar
• Li K, Wohlford-Lenane C, Perlman S, et al. Middle east respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J Infect Dis. 2016;213(5):712–722. doi: 10.1093/infdis/jiv499
   PubMed Web of Science ®Google Scholar
• Roberts A, Deming D, Paddock CD, et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLOS Pathog. 2007;3(1):e5. doi: 10.1371/journal.ppat.0030005
   PubMed Web of Science ®Google Scholar
• Leist SR, Dinnon KH, Schäfer A, et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell. 2020;183(4):1070–1085.e12. doi: 10.1016/j.cell.2020.09.050
   PubMed Web of Science ®Google Scholar
• Dinnon KH, Leist SR, Schäfer A, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586(7830):560–566. doi: 10.1038/s41586-020-2708-8
   PubMed Web of Science ®Google Scholar
• Li K, Wohlford-Lenane CL, Channappanavar R, et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proceedings of the National Academy of Sciences. 2017;114:E3119–E3128.
   PubMed Web of Science ®Google Scholar
• Israelow B, Song E, Mao T, et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J Exp Med. 2020;217(12):e20201241. doi: 10.1084/jem.20201241
   PubMed Web of Science ®Google Scholar
• Hassan AO, Case JB, Winkler ES, et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell. 2020;182(3):744–753.e4. doi: 10.1016/j.cell.2020.06.011
   PubMed Web of Science ®Google Scholar
• Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21:162–177. doi: 10.1038/s41579-022-00841-7
   PubMed Web of Science ®Google Scholar
• Pan T, Chen R, He X, et al. Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. Signal Transduct Target Ther. 2021;6(1):420. doi: 10.1038/s41392-021-00848-1
   PubMed Web of Science ®Google Scholar
• Stone S, Rothan HA, Natekar JP, et al. SARS-CoV-2 variants of concern infect the respiratory tract and induce inflammatory response in wild-type laboratory mice. Viruses. 2021;14(1):27. doi: 10.3390/v14010027
   PubMed Web of Science ®Google Scholar
• Xu J, Zhong S, Liu J, et al. Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. Clin Infect Dis. 2005;41(8):1089–1096. doi: 10.1086/444461
   PubMed Web of Science ®Google Scholar
• Hung ECW, Chim SSC, Chan PKS, et al. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. Clin Chem. 2003;49(12):2108–2109. doi: 10.1373/clinchem.2003.025437
   PubMed Web of Science ®Google Scholar
• Yang X, Deng W, Tong Z, et al. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. Comp Med. 2007;57(5):450–459.
   PubMed Web of Science ®Google Scholar
• Tseng C-TK, Huang C, Newman P, et al. Severe Acute Respiratory Syndrome Coronavirus Infection of Mice Transgenic for the Human Angiotensin-Converting Enzyme 2 Virus Receptor. J Virol. 2007;81(3):1162–1173. doi: 10.1128/JVI.01702-06
   PubMed Web of Science ®Google Scholar
• Moreau GB, Burgess SL, Sturek JM, et al. Evaluation of K18-hACE2 mice as a model of SARS-CoV-2 infection. Am J Trop Med Hyg. 2020;103(3):1215–1219. doi: 10.4269/ajtmh.20-0762
   PubMed Web of Science ®Google Scholar
• Rathnasinghe R, Strohmeier S, Amanat F, et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect. 2020;9(1):2433–2445. doi: 10.1080/22221751.2020.1838955
   PubMed Web of Science ®Google Scholar
• Zheng J, Wong L-YR, Li K, et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature. 2021;589(7843):603–607. doi: 10.1038/s41586-020-2943-z
   PubMed Web of Science ®Google Scholar
• Golden JW, Cline CR, Zeng X, et al. Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight. 2020;5(19):e142032. doi: 10.1172/jci.insight.142032
   PubMed Web of Science ®Google Scholar
• Winkler ES, Bailey AL, Kafai NM, et al. SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020;21(11):1327–1335. doi: 10.1038/s41590-020-0778-2
   PubMed Web of Science ®Google Scholar
• Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological features of covid-19. N Engl J Med. 2020;383(10):989–992. doi: 10.1056/NEJMc2019373
   PubMed Web of Science ®Google Scholar
• Chen M, Shen W, Rowan NR, et al. Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication. Eur Respir J. 2020;56(3):2001948. doi: 10.1183/13993003.01948-2020
   PubMed Web of Science ®Google Scholar
• Ye Q, Zhou J, He Q, et al. SARS-CoV-2 infection in the mouse olfactory system. Cell Discov. 2021;7(1):49. doi: 10.1038/s41421-021-00290-1
   PubMed Web of Science ®Google Scholar
• Verma AK, Zheng J, Meyerholz DK, et al. SARS-CoV-2 infection of sustentacular cells disrupts olfactory signaling pathways. JCI Insight. 2022;7(24). doi:10.1172/jci.insight.160277.
   Web of Science ®Google Scholar
• Menachery VD,Yount Jr BL, Sims AC, et al. SARS-like WIV1-CoV poised for human emergence. Proceedings of the National Academy of Sciences. 2016;113:3048–3053.
   PubMed Web of Science ®Google Scholar
• Jiang R-D, Liu M-Q, Chen Y, et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell. 2020;182(1):50–58.e8. doi: 10.1016/j.cell.2020.05.027
   PubMed Web of Science ®Google Scholar
• Zhang W, Golynker I, Brosh R, et al. Mouse genome rewriting and tailoring of three important disease loci. Nature. 2023;623(7986):423–431. doi: 10.1038/s41586-023-06675-4
   PubMedGoogle Scholar
• Rai P, Chuong C, LeRoith T, et al. Adenovirus transduction to express human ACE2 causes obesity-specific morbidity in mice, impeding studies on the effect of host nutritional status on SARS-CoV-2 pathogenesis. Virology. 2021;563:98–106. doi: 10.1016/j.virol.2021.08.014
   PubMed Web of Science ®Google Scholar
• Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812–827.e19. doi: 10.1016/j.cell.2020.06.043
   PubMed Web of Science ®Google Scholar
• Lorenzo-Redondo R, Nam HH, Roberts SC, et al. A clade of SARS-CoV-2 viruses associated with lower viral loads in patient upper airways. EBioMedicine. 2020;62:103112. doi: 10.1016/j.ebiom.2020.103112
   PubMed Web of Science ®Google Scholar
• Hou YJ, Chiba S, Halfmann P, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020;370(6523):1464–1468. doi: 10.1126/science.abe8499
   PubMed Web of Science ®Google Scholar
• Zhou B, Thao TTN, Hoffmann D, et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature. 2021;592(7852):122–127. doi: 10.1038/s41586-021-03361-1
   PubMed Web of Science ®Google Scholar
• Rathnasinghe R, Jangra S, Ye C, et al. Characterization of SARS-CoV-2 spike mutations important for infection of mice and escape from human immune sera. Nat Commun. 2022;13(1):3921. doi: 10.1038/s41467-022-30763-0
   PubMed Web of Science ®Google Scholar
• Gu H, Chen Q, Yang G, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 2020;369(6511):1603–1607. doi: 10.1126/science.abc4730
   PubMed Web of Science ®Google Scholar
• Yu W, Wang J, Yang Y, et al. SARS-CoV-2 omicron (B.1.1.529) infection in rhesus macaques, hamsters, and BALB/c mice with severe lung histopathological damage. J Med Virol. 2023;95(6):e28846. doi: 10.1002/jmv.28846
   PubMed Web of Science ®Google Scholar
• Halfmann PJ, Iida S, Iwatsuki-Horimoto K, et al. SARS-CoV-2 omicron virus causes attenuated disease in mice and hamsters. Nature. 2022;603(7902):687–692. doi: 10.1038/s41586-022-04441-6
   PubMed Web of Science ®Google Scholar
• Shuai H, Chan JF-W, Yuen T-T-T, et al. Emerging SARS-CoV-2 variants expand species tropism to murines. EBioMedicine. 2021;73:103643. doi: 10.1016/j.ebiom.2021.103643
   PubMed Web of Science ®Google Scholar
• Tracking SARS-CoV-2 variants. https://www.who.int/activities/tracking-SARS-CoV-2-variants.
   Google Scholar
• Hu F-H, Jia Y-J, Zhao D-Y, et al. Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 omicron and delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019–positive patients. Clin Microbiol Infect. 2023;29(7):835–844. doi: 10.1016/j.cmi.2023.03.017
   PubMed Web of Science ®Google Scholar
• Rizvi ZA, Dandotiya J, Sadhu S, et al. Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 transgenic mice. Commun Biol. 2023;6(1):935. doi: 10.1038/s42003-023-05263-6
   PubMedGoogle Scholar
• Shuai H, Chan JF-W, Hu B, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 omicron. Nature. 2022;603(7902):693–699. doi: 10.1038/s41586-022-04442-5
   PubMed Web of Science ®Google Scholar
• Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77–81. doi: 10.1126/science.abc1932
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Huang B, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713–721.e9. doi: 10.1016/j.cell.2020.06.008
   PubMed Web of Science ®Google Scholar
• Zhang N-N, Li X-F, Deng Y-Q, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182(5):1271–1283.e16. doi: 10.1016/j.cell.2020.07.024
   PubMed Web of Science ®Google Scholar
• Martinez DR, Schäfer A, Leist SR, et al. Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Rep. 2021;36(4):109450. doi: 10.1016/j.celrep.2021.109450
   PubMed Web of Science ®Google Scholar
• A portfolio of COVID-19 platforms. The Jackson Laboratory https://www.jax.org/jax-mice-and-services/research-continuity/hace2.
   Google Scholar
• Martina BEE, Haagmans BL, Kuiken T, et al. SARS virus infection of cats and ferrets. Nature. 2003;425(6961):915–915. doi: 10.1038/425915a
   PubMed Web of Science ®Google Scholar
• Chu Y-K, Ali GD, Jia F, et al. The SARS-CoV ferret model in an infection–challenge study. Virology. 2008;374(1):151–163. doi: 10.1016/j.virol.2007.12.032
   PubMed Web of Science ®Google Scholar
• Kim Y-I, Kim S-G, Kim S-M, et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe. 2020;27(5):704–709.e2. doi: 10.1016/j.chom.2020.03.023
   PubMed Web of Science ®Google Scholar
• Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127–20. doi: 10.1128/JVI.00127-20
   PubMed Web of Science ®Google Scholar
• Raj VS, Smits SL, Provacia LB, et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the middle east respiratory syndrome coronavirus. J Virol. 2014;88(3):1834–1838. doi: 10.1128/JVI.02935-13
   PubMed Web of Science ®Google Scholar
• Pulit-Penaloza JA, Belser JA, Sun X, et al. Comparative assessment of severe acute respiratory syndrome coronavirus 2 variants in the ferret model. MBio. 2022;13(5):e0242122. doi: 10.1128/mbio.02421-22
   PubMed Web of Science ®Google Scholar
• Lieber CM, Cox RM, Sourimant J, et al. SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model. Nat Commun. 2022;13(1):4416. doi: 10.1038/s41467-022-32045-1
   PubMed Web of Science ®Google Scholar
• van de Ven K, van Dijken H, Wijsman L, et al. Pathology and immunity after SARS-CoV-2 infection in male ferrets is affected by age and inoculation route. Front Immunol. 2021;12. doi: 10.3389/fimmu.2021.750229
   Google Scholar
• Ryan KA, Bewley KR, Fotheringham SA, et al. Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity. Nat Commun. 2021;12(1):81. doi: 10.1038/s41467-020-20439-y
   PubMed Web of Science ®Google Scholar
• Shi J, Wen Z, Zhong G, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. Science. 2020;368(6494):1016–1020. doi: 10.1126/science.abb7015
   PubMed Web of Science ®Google Scholar
• Richard M, Kok A, de Meulder D, et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nat Commun. 2020;11(1):3496. doi: 10.1038/s41467-020-17367-2
   PubMed Web of Science ®Google Scholar
• An D, Li K, Rowe DK, et al. Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5–based COVID-19 vaccine. Sci Adv. 2021;7(27):eabi5246. doi: 10.1126/sciadv.abi5246
   PubMed Web of Science ®Google Scholar
• Boley PA, Lee CM, Schrock J, et al. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines. J Nanobiotechnology. 2023;21(1):60. doi: 10.1186/s12951-023-01816-3
   PubMed Web of Science ®Google Scholar
• Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2021;6(1):11–18. doi: 10.1038/s41564-020-00835-2
   PubMed Web of Science ®Google Scholar
• Park S-J, Yu K-M, Kim Y-I, et al. Antiviral efficacies of FDA-Approved drugs against SARS-CoV-2 infection in ferrets. MBio. 2020;11(3). doi: 10.1128/mbio.01114-20
   Web of Science ®Google Scholar
• Roberts A, Vogel L, Guarner J, et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol. 2005;79(1):503–511. doi: 10.1128/JVI.79.1.503-511.2005
   PubMed Web of Science ®Google Scholar
• Chan JF-W, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a Golden Syrian hamster Model: implications for disease pathogenesis and transmissibility. Clinl Infect Dis. 2020;325. doi: 10.1093/cid/ciaa325
   Google Scholar
• Imai M, Iwatsuki-Horimoto K, Hatta M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A. 2020;117(28):16587–16595. doi: 10.1073/pnas.2009799117
   PubMed Web of Science ®Google Scholar
• Rosenke K, Meade-White K, Letko M, et al. Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. Emerg Microbes Infect. 2020;9(1):2673–2684. doi: 10.1080/22221751.2020.1858177
   PubMed Web of Science ®Google Scholar
• Trimpert J, Vladimirova D, Dietert K, et al. The roborovski dwarf hamster is a highly susceptible model for a rapid and fatal course of SARS-CoV-2 infection. Cell Rep. 2020;33(10):108488. doi: 10.1016/j.celrep.2020.108488
   PubMed Web of Science ®Google Scholar
• Zhai C, Wang M, Chung H-J, et al. Roborovski hamster (Phodopus roborovskii) strain SH101 as a systemic infection model of SARS-CoV-2. Virulence. 2021;12(1):2430–2442. doi: 10.1080/21505594.2021.1972201
   PubMed Web of Science ®Google Scholar
• Bertzbach LD, Vladimirova D, Dietert K, et al. SARS-CoV-2 infection of Chinese hamsters (cricetulus griseus) reproduces COVID-19 pneumonia in a well-established small animal model. Transbound Emerg Dis. 2021;68(3):1075–1079. doi: 10.1111/tbed.13837
   PubMed Web of Science ®Google Scholar
• Gruber AD, Firsching TC, Trimpert J, et al. Hamster models of COVID-19 pneumonia reviewed: how human can they be? Vet Pathol. 2022;59(4):528–545. doi: 10.1177/03009858211057197
   PubMed Web of Science ®Google Scholar
• de Melo GD, Lazarini F, Levallois S, et al. COVID-19–related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci, Trans Med. 2021;13(596):eabf8396. doi: 10.1126/scitranslmed.abf8396
   PubMed Web of Science ®Google Scholar
• Sia SF, Yan L-M, Chin AWH, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020;583(7818):834–838. doi: 10.1038/s41586-020-2342-5
   PubMed Web of Science ®Google Scholar
• Song Z, Bao L, Yu P, et al. SARS-CoV-2 causes a systemically multiple organs damages and dissemination in hamsters. Front Microbiol. 2021;11. doi: 10.3389/fmicb.2020.618891
   Web of Science ®Google Scholar
• Osterrieder N, Bertzbach LD, Dietert K, et al. Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters. Viruses. 2020;12(7):779. doi: 10.3390/v12070779
   PubMed Web of Science ®Google Scholar
• Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. doi: 10.1016/S0140-6736(20)30937-5
   PubMed Web of Science ®Google Scholar
• Dhakal S, Ruiz-Bedoya CA, Zhou R, et al. Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden syrian hamster model. MBio. 2021;12(4):e0097421. doi: 10.1128/mBio.00974-21
   PubMed Web of Science ®Google Scholar
• Oishi K, Horiuchi S, Frere J, et al. A diminished immune response underlies age-related SARS-CoV-2 pathologies. Cell Rep. 2022;39(13):111002. doi: 10.1016/j.celrep.2022.111002
   PubMed Web of Science ®Google Scholar
• Mohandas S, Shete A, Kumar A, et al. Comparative pathogenicity of BA.2.12, BA.5.2 and XBB.1 with the delta variant in Syrian hamsters. Front Microbiol. 2023;14:1183763. doi: 10.3389/fmicb.2023.1183763
   PubMed Web of Science ®Google Scholar
• Yuan S, Ye Z-W, Liang R, et al. Pathogenicity, transmissibility, and fitness of SARS-CoV-2 omicron in Syrian hamsters. Science. 2022;377(6604):428–433. doi: 10.1126/science.abn8939
   PubMed Web of Science ®Google Scholar
• Uraki R, Halfmann PJ, Iida S, et al. Characterization of SARS-CoV-2 omicron BA.4 and BA.5 isolates in rodents. Nature. 2022;612(7940):540–545. doi: 10.1038/s41586-022-05482-7
   PubMed Web of Science ®Google Scholar
• Sharma S, Vercruysse T, Sanchez-Felipe L, et al. Updated vaccine protects against SARS-CoV-2 variants including omicron (B.1.1.529) and prevents transmission in hamsters. Nat Commun. 2022;13(1):6644. doi: 10.1038/s41467-022-34439-7
   PubMed Web of Science ®Google Scholar
• Abdelnabi R, Foo CS, Zhang X, et al. The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. Antiviral Res. 2022;198:105253. doi: 10.1016/j.antiviral.2022.105253
   PubMed Web of Science ®Google Scholar
• Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 omicron variant. Nature. 2022;603(7902):700–705. doi: 10.1038/s41586-022-04462-1
   PubMed Web of Science ®Google Scholar
• Li J, Yu X, Hu S, et al. COVID-19 targets the right lung. Crit Care. 2020;24(1):339. doi: 10.1186/s13054-020-03033-y
   PubMed Web of Science ®Google Scholar
• Andreotti S, Altmüller J, Quedenau C, et al. De novo-whole genome assembly of the roborovski dwarf hamster (phodopus roborovskii) genome: an animal model for severe/critical COVID-19. Genome Biol Evol. 2022;14(7):evac100. doi: 10.1093/gbe/evac100
   PubMed Web of Science ®Google Scholar
• Fouchier RAM, Kuiken, T., Schutten, M., et al. Koch’s postulates fulfilled for SARS virus. Nature. 2003;423:240–240. doi: 10.1038/423240a 6937
   PubMed Web of Science ®Google Scholar
• McAuliffe J, Vogel L, Roberts A, et al. Replication of SARS coronavirus administered into the respiratory tract of African green, rhesus and cynomolgus monkeys. Virology. 2004;330(1):8–15. doi: 10.1016/j.virol.2004.09.030
   PubMed Web of Science ®Google Scholar
• Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med. 2004;10(3):290–293. doi: 10.1038/nm1001
   PubMed Web of Science ®Google Scholar
• Rowe T, Gao G, Hogan RJ, et al. Macaque Model for Severe Acute Respiratory Syndrome. J Virol. 2004;78(20):11401–11404. doi: 10.1128/JVI.78.20.11401-11404.2004
   PubMed Web of Science ®Google Scholar
• Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362(9380):263–270. doi: 10.1016/S0140-6736(03)13967-0
   PubMed Web of Science ®Google Scholar
• de Wit E, Rasmussen, AL, and Falzarano D,et al. Middle east respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proceedings of the National Academy of Sciences. 2013;110:16598–16603.
   PubMed Web of Science ®Google Scholar
• Rockx B, Kuiken T, Herfst S, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science. 2020;368(6494):1012–1015. doi: 10.1126/science.abb7314
   PubMed Web of Science ®Google Scholar
• Lu S, Zhao Y, Yu W, et al. Comparison of nonhuman primates identified the suitable model for COVID-19. Sig Transduct Target Ther. 2020;5(1):1–9. doi: 10.1038/s41392-020-00269-6
   PubMed Web of Science ®Google Scholar
• Shan C, Yao Y-F, Yang X-L, et al. Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in rhesus macaques. Cell Res. 2020;30(8):670–677. doi: 10.1038/s41422-020-0364-z
   PubMed Web of Science ®Google Scholar
• Munster VJ, Feldmann F, Williamson BN, et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature. 2020;585(7824):268–272. doi: 10.1038/s41586-020-2324-7
   PubMed Web of Science ®Google Scholar
• Singh DK, Singh B, Ganatra SR, et al. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets. Nat Microbiol. 2021;6(1):73–86. doi: 10.1038/s41564-020-00841-4
   PubMed Web of Science ®Google Scholar
• Yu P, Qi F, Xu Y, et al. Age-related rhesus macaque models of COVID-19. AMEM. 2020;3(1):93–97. doi: 10.1002/ame2.12108
   Google Scholar
• Johnston SC, Ricks KM, Jay A, et al. Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure. PloS One. 2021;16(2):e0246366. doi: 10.1371/journal.pone.0246366
   PubMed Web of Science ®Google Scholar
• Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020;369(6505):812–817. doi: 10.1126/science.abc4776
   PubMed Web of Science ®Google Scholar
• Blair RV, Vaccari M, Doyle-Meyers LA, et al. Acute respiratory distress in aged, SARS-CoV-2–infected African green monkeys but not rhesus macaques. Am J Pathol. 2021;191(2):274–282. doi: 10.1016/j.ajpath.2020.10.016
   PubMed Web of Science ®Google Scholar
• Woolsey C, Borisevich V, Prasad AN, et al. Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nat Immunol. 2021;22(1):86–98. doi: 10.1038/s41590-020-00835-8
   PubMed Web of Science ®Google Scholar
• Hartman AL, Nambulli S, McMillen CM, et al. SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and shedding of infectious virus from both respiratory and gastrointestinal tracts. PLOS Pathogens. 2020;16(9):e1008903. doi: 10.1371/journal.ppat.1008903
   PubMed Web of Science ®Google Scholar
• Lankau EW, Turner PV, Mullan RJ, et al. Use of nonhuman primates in research in North America. J Am Assoc Lab Anim Sci. 2014;53(3):278–282.
   PubMed Web of Science ®Google Scholar
• Carlsson H-E, Schapiro SJ, Farah I, et al. Use of primates in research: a global overview. Am J Primatol. 2004;63(4):225–237. doi: 10.1002/ajp.20054
   PubMed Web of Science ®Google Scholar
• Pedersen RM, Tornby DS, Bang LL, et al. Rectally shed SARS-CoV-2 in COVID-19 inpatients is consistently lower than respiratory shedding and lacks infectivity. Clin Microbiol Infect. 2022;28(2):304.e1–304.e3. doi: 10.1016/j.cmi.2021.10.023
   PubMed Web of Science ®Google Scholar
• Oh T, Kim G, Baek SH, et al. Comparative spatial transcriptomic profiling of severe acute respiratory syndrome coronavirus 2 delta and omicron variants infections in the lungs of cynomolgus macaques. J Med Virol. 2023;95(6):e28847. doi: 10.1002/jmv.28847
   PubMed Web of Science ®Google Scholar
• van Doremalen N, Singh M, Saturday TA, et al. SARS-CoV-2 omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to delta. Sci Adv. 2022;8(46):eade1860. doi: 10.1126/sciadv.ade1860
   PubMed Web of Science ®Google Scholar
• Munster VJ, Flagg M, Singh M, et al. Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. Sci Adv. 2021;7(43):eabj3627. doi: 10.1126/sciadv.abj3627
   PubMed Web of Science ®Google Scholar
• Gagne M, Moliva JI, Foulds KE, et al. mRNA-1273 or mRNA-omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from omicron. Cell. 2022;185(9):1556–1571.e18. doi: 10.1016/j.cell.2022.03.038
   PubMed Web of Science ®Google Scholar
• Chandrashekar A, Yu J, McMahan K, et al. Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. Cell. 2022;185(9):1549–1555.e11. doi: 10.1016/j.cell.2022.03.024
   PubMed Web of Science ®Google Scholar
• Solforosi L, Costes LMM, Tolboom JTBM, et al. Booster with Ad26.COV2.S or omicron-adapted vaccine enhanced immunity and efficacy against sars-cov-2 omicron in macaques. Nat Commun. 2023;14(1):1944. doi: 10.1038/s41467-023-37715-2
   PubMed Web of Science ®Google Scholar
• Chang MC, Hild S, Grieder F. Nonhuman primate models for SARS-CoV-2 research: consider alternatives to macaques. Lab Anim. 2021;50(5):113–114. doi: 10.1038/s41684-021-00755-6
   Web of Science ®Google Scholar
• Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585(7824):273–276. doi: 10.1038/s41586-020-2423-5
   PubMed Web of Science ®Google Scholar
• Hoang TN, Pino M, Boddapati AK, et al. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell. 2021;184(2):460–475.e21. doi: 10.1016/j.cell.2020.11.007
   PubMed Web of Science ®Google Scholar
• Cáceres CJ, Cardenas-Garcia S, Carnaccini S, et al. Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. Sci Rep. 2021;11(1):9609. doi: 10.1038/s41598-021-89013-w
   PubMed Web of Science ®Google Scholar
• Villadiego J, García-Arriaza J, Ramírez-Lorca R, et al. Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate. Nat Neurosci. 2023;26(2):226–238. doi: 10.1038/s41593-022-01242-y
   PubMed Web of Science ®Google Scholar
• Prompetchara E, Ketloy C, Alameh M-G, et al. Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice. Nat Commun. 2023;14(1):2309. doi: 10.1038/s41467-023-37795-0
   PubMed Web of Science ®Google Scholar
• Tarrés-Freixas F, Trinité B, Pons-Grífols A, et al. Heterogeneous infectivity and pathogenesis of SARS-CoV-2 variants beta, delta and omicron in transgenic K18-hACE2 and wildtype mice. Front Microbiol. 2022;13:840757. doi: 10.3389/fmicb.2022.840757
   PubMed Web of Science ®Google Scholar
• Aiolfi R, Ahmed J, de la Torre JC, et al. Sars-cov-2 infection promotes endothelial dysfunction and thrombosis in a mouse model of COVID-19. Blood. 2021;138(Supplement 1):999. doi: 10.1182/blood-2021-148713
   Google Scholar
• Chen Y, Li C, Liu F, et al. Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model. Emerg Microbes Infect. 2022;11(1):368–383. doi: 10.1080/22221751.2022.2026741
   PubMed Web of Science ®Google Scholar
• Sriramula S, Theobald D, Parekh RU, et al. Emerging role of kinin B1 receptor in persistent neuroinflammation and neuropsychiatric symptoms in mice following recovery from SARS-CoV-2 infection. Cells. 2023;12(16):2107. doi: 10.3390/cells12162107
   PubMed Web of Science ®Google Scholar
• Sadhu S, Dalal R, Dandotiya J, et al. IL-9 aggravates SARS-CoV-2 infection and exacerbates associated airway inflammation. Nat Commun. 2023;14(1):4060. doi: 10.1038/s41467-023-39815-5
   PubMed Web of Science ®Google Scholar
• Geng J, Chen L, Yuan Y, et al. CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. Signal Transduct Target Ther. 2021;6(1):347. doi: 10.1038/s41392-021-00760-8
   PubMed Web of Science ®Google Scholar
• Wu J, Chen L, Qin C, et al. CD147 contributes to SARS-CoV-2-induced pulmonary fibrosis. Signal Transduct Target Ther. 2022;7(1):382. doi: 10.1038/s41392-022-01230-5
   PubMed Web of Science ®Google Scholar
• Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443–449. doi: 10.1038/s41586-020-2548-6
   PubMed Web of Science ®Google Scholar
• Alsoussi WB, Turner JS, Case JB, et al. A potently neutralizing antibody protects mice against SARS-CoV-2 infection. J Immunol. 2020;205(4):915–922. doi: 10.4049/jimmunol.2000583
   PubMed Web of Science ®Google Scholar
• Tian J-H, Patel N, Haupt R, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12(1):372. doi: 10.1038/s41467-020-20653-8
   PubMed Web of Science ®Google Scholar
• Yong KSM, Anderson DE, Zheng AKE, et al. Comparison of infection and human immune responses of two SARS-CoV-2 strains in a humanized hACE2 NIKO mouse model. Sci Rep. 2023;13(1):12484. doi: 10.1038/s41598-023-39628-y
   PubMed Web of Science ®Google Scholar
• Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–571. doi: 10.1038/s41586-020-2622-0
   PubMed Web of Science ®Google Scholar
• Wu S, Zhong G, Zhang J, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11(1):4081. doi: 10.1038/s41467-020-17972-1
   PubMed Web of Science ®Google Scholar
• Rogers TF, Zhao F, Huang D, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956–963. doi: 10.1126/science.abc7520
   PubMed Web of Science ®Google Scholar
• Hermet P, Delache B, Herate C, et al. Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on spike and provides antiviral protection through inhalation-based delivery in non-human primates. PLOS Pathog. 2023;19(8):e1011532. doi: 10.1371/journal.ppat.1011532
   PubMed Web of Science ®Google Scholar
• Neary M, Sharp J, Gallardo-Toledo E, et al. Evaluation of Nafamostat as chemoprophylaxis for SARS-CoV-2 infection in hamsters. Viruses. 2023;15(8):1744. doi: 10.3390/v15081744
   PubMed Web of Science ®Google Scholar
• de Moor WRJ, Williamson A-L, Schäfer G, et al. LSDV-Vectored SARS-CoV-2 S and N vaccine protects against severe clinical disease in hamsters. Viruses. 2023;15(7):1409. doi: 10.3390/v15071409
   PubMed Web of Science ®Google Scholar
• Rosenke K, Okumura A, Lewis MC, et al. Molnupiravir inhibits SARS-CoV-2 variants including omicron in the hamster model. JCI Insight. 2022;7(13):e160108. doi: 10.1172/jci.insight.160108
   PubMed Web of Science ®Google Scholar
• Wyler E, Adler JM, Eschke K, et al. Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomics. Mol Ther. 2022;30(5):1952–1965. doi: 10.1016/j.ymthe.2022.03.014
   PubMed Web of Science ®Google Scholar
• de Melo GD, Perraud V, Alvarez F, et al. Neuroinvasion and anosmia are independent phenomena upon infection with SARS-CoV-2 and its variants. Nat Commun. 2023;14(1):4485. doi: 10.1038/s41467-023-40228-7
   PubMed Web of Science ®Google Scholar
• Yang Z, Johnson BA, Meliopoulos VA, et al. Interaction between host G3BP and viral nucleocapsid protein regulates SARS-CoV-2 replication. bioRxiv. 2023;2023(6.29.546885). doi: 10.1101/2023.06.29.546885
   Google Scholar
• Abdelaziz MO, Raftery MJ, Weihs J, et al. Early protective effect of a (“pan”) coronavirus vaccine (PanCovac) in Roborovski dwarf hamsters after single-low dose intranasal administration. Front Immunol. 2023;14:1166765. doi: 10.3389/fimmu.2023.1166765
   PubMed Web of Science ®Google Scholar
• McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630–634. doi: 10.1038/s41586-020-03041-6
   PubMed Web of Science ®Google Scholar
• Willcox AC, Sung K, Garrett ME, et al. Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques. PLOS Pathog. 2022;18(4):e1010155. doi: 10.1371/journal.ppat.1010155
   PubMed Web of Science ®Google Scholar
• Everett HE, Lean FZX, Byrne AMP, et al. Intranasal infection of ferrets with SARS-CoV-2 as a model for asymptomatic human infection. Viruses. 2021;13(1):113. doi: 10.3390/v13010113
   PubMed Web of Science ®Google Scholar
• Sefik E, Israelow B, Mirza H, et al. A humanized mouse model of chronic COVID-19. Nat Biotechnol. 2022;40(6):906–920. doi: 10.1038/s41587-021-01155-4
   PubMed Web of Science ®Google Scholar